Serina Therapeutics Advances SER-252 for Parkinson's Disease
Serina Therapeutics, Inc. (NYSE American: SER), a biotechnology company focused on innovative treatments for neurological conditions, is taking significant steps in its clinical journey. The firm recently received encouraging feedback from the U.S. Food and Drug Administration (FDA), which supports the development of its investigational drug, SER-252, intended to help individuals battling advanced Parkinson’s disease.
FDA Feedback and Registration Plans
Based on the insights gained from a recent Type B meeting with the FDA, Serina is poised to initiate a registrational study program for SER-252 under the 505(b)(2) NDA regulatory pathway. This exciting development plans to move forward with a U.S. IND filing expected in late 2025, with patient enrollment anticipated to commence in early 2026. In the meantime, dosing for patients in Australia is set to begin in Q4 2025, marking a crucial step in the global study.
CEO Vision and Commitment
Steve Ledger, Chief Executive Officer of Serina Therapeutics, expressed optimism regarding the FDA's affirmation of their drug's potential. He stated, “People living with advanced Parkinson’s need more consistent relief from motor fluctuations, and our data to date suggest that SER-252 may reliably improve daily function.” This feedback provides the company the confidence to streamline the NDA process while generating robust data to support regulatory review, all while focusing on enhancing patient outcomes.
Strategic Drug Development Approach
In conversations with the FDA, Serina outlined an approach that capitalizes on existing knowledge about apomorphine, utilizing their proprietary POZ Platform technology. The initial study design includes a pharmacokinetic (PK) bridging component aligned with an approved apomorphine product. This approach is a strategic choice, ensuring that Serina’s studies meet the standard clinical and nonclinical requirements set forth by the FDA, paving the way for successful regulatory submissions.
Pipeline Beyond SER-252
Serina is not stopping with SER-252. The company envisions a pipeline of POZ-enabled small molecules that could potentially follow similar regulatory pathways when suitable. Ledger remarked on the necessity of each program to adhere to its scientific guidelines while maintaining a dialogue with the FDA. This commitment emphasizes Serina’s dedication to developing new treatment options for patients efficiently and effectively.
Details of the SER-252 Registrational Study
The SER-252-1b study will be a randomized, double-blind, placebo-controlled Phase 1b trial involving subcutaneous administration of SER-252. This trial includes both single and multiple-ascending-dose components, aimed at assessing the safety and tolerability, in addition to pharmacokinetic evaluations. Safety and efficacy will be carefully monitored with exploratory measures focusing on motor function ratings.
About SER-252 and Its Mechanism
SER-252 is a promising investigational therapy, offering continuous dopaminergic stimulation (CDS) through infrequent subcutaneous injections. By potentially reducing motor fluctuations and improving the daily lives of patients with advanced Parkinson's, SER-252 leverages Enable Injections’ enFuse technology to provide a long-acting, easy-to-administer treatment option.
The POZ Technology Behind Serina’s Innovation
At the core of SER-252’s development is Serina’s unique POZ Platform technology. This innovative system, based on a synthetic polymer, enhances drug delivery precision and efficacy while minimizing adverse effects associated with current treatments. By aiming to stabilize drug levels in the bloodstream, Serina seeks to advance therapeutic options for those with narrow therapeutic indices.
About Serina Therapeutics
Serina Therapeutics is committed to advancing science in the biotechnology field, particularly in treating neurological disorders. The company's focus on developing a diverse range of drug candidates promises to enhance patient care through innovative delivery mechanisms and advanced therapies. Headquartered in Huntsville, Alabama, Serina operates on the cutting edge of biotechnology, contributing valuable insights and options for medical professionals and patients alike.
Frequently Asked Questions
What is SER-252?
SER-252 is an investigational drug using the POZ Platform, designed to provide innovative treatment for advanced Parkinson's disease.
When does patient dosing start for SER-252?
Patient dosing is expected to begin in Australia in the fourth quarter of 2025.
What does the FDA feedback mean for Serina?
The FDA’s feedback indicates support for Serina's clinical study design, paving the way for a registrational trial under the 505(b)(2) NDA pathway.
How does the POZ technology work?
POZ technology enhances drug delivery by maintaining stable blood levels of medication while reducing adverse side effects associated with current treatment regimens.
Where is Serina Therapeutics located?
Serina Therapeutics is headquartered in Huntsville, Alabama, within the HudsonAlpha Institute of Biotechnology.
